Combination Drug Therapy Offers Hope For Malaria Treatment

Two articles and a Commentary in this week’s issue highlight how combination therapy offers the best hope for tackling drug resistance for the millions of people worldwide affected by malaria.

Drug resistance is the main barrier to effective malaria treatment. Artemisinin (extract of sweet wormwood , commonly used in Chinese herbal medicine) and its derivatives, artemether and artesunate, are of potential importance as other malarial drugs have been associated with microbial resistance.

A meta-analysis by the International Artemisinin Study Group of 16 randomised trials (12 from sub-Saharan Africa, three from Thailand, one from Peru) shows that artesunate was highly effective in treating malaria when added to other antimalarial drugs. Around 6000 patients were participants in the studies. Artesunate decreased parasite failure by around 80% and doubled the rate of parasite clearance compared with patients given standard malaria treatment.

Patrick E Duffy and Theonest K Mutabingwa consider in an accompanying Commentary (p 3) the policy implications for the use of artemisinin combination treatment (ACT) in different countries. They comment: “Will ACT reduce malaria incidence and prevent the emergence and spread of drug-resistant parasites in Africa, as occurred in southeast Asia? Only additional research will answer these questions. However, because of differences in epidemiology and intensity of transmission, reducing malaria incidence in Africa will be challenging.”

A study from Vietnam in this week’s issue (p 18) also assesses combination treatment for malaria. Tran Tinh Hien and colleagues found that the new combination dihydroartemisinin-piperaquine, formulated in a single tablet, is highly efficacious in Vietnam, where multidrug-resistant parasites are common. Authors of the Commentary state: “Dihydroartemisinin-piperaquine has a cost advantage (US$1 for an adult treatment) that brings it within reach of many but not all consumers, and encourages funding agencies to sponsor programmes that deliver these needed medicines to poorer countries.”

Media Contact

Richard Lane alfa

Further information:

http://www.lancet.com

All news from this category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to the Homepage

Comments (0)

Write comment

Latest posts

Just a few atoms thick: New functional materials developed

Using the smallest “construction set” in the world, a research team from the universities of Marburg, Giessen and Paderborn is designing new materials for computer chips, light-emitting diodes and solar…

Researchers develop new metal-free, recyclable polypeptide battery

– that degrades on demand … This could result in battery production moving away from strategic elements like cobalt. The introduction of lithium-ion (Li-ion) batteries has revolutionized technology as a…

Artificial lungs as organ replacement

DFG priority program funds four MHH projects with 1.6 million euros. For people with severe lung diseases, transplantation of a healthy organ is often the only chance of survival. But…

Partners & Sponsors